Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - calcitriol 0.5ug;   - soft gelatin capsule - 0.5 mcg - active: calcitriol 0.5ug   excipient: butylated hydroxyanisole butylated hydroxytoluene coconut oil gelatin glycerol iron oxide black patent blue v purified water quinoline yellow shellac sorbitol titanium dioxide - · established postmenopausal osteoporosis

Amerika Serikat - Inggris - NLM (National Library of Medicine)

mayne pharma commercial llc. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in adults and pediatric patients 2 years and older. the safety and effectiveness of calcitriol ointment in patients with known or suspected disorders of calcium metabolism have not been evaluated. none risk summary available data from pregnancies that occurred during the clinical development of calcitriol ointment and published case series of oral and intravenous calcitriol use in pregnant women have not identified a drug associated risk for major birth defects, miscarriages, or adverse maternal or fetal outcomes. in animal reproduction studies, topical administration of calcitriol to pregnant rabbits during the period of organogenesis resulted in an increased incidence of fetal deaths, as well as an increased incidence of minor skeletal abnormalities (see data) . the available data do not allow the calculation of relevant comparisons between the systemic exposures of calcitriol observed in animal studies t

Amerika Serikat - Inggris - NLM (National Library of Medicine)

kaiser foundation hospitals - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol 0.25 ug

Amerika Serikat - Inggris - NLM (National Library of Medicine)

galderma laboratories, l.p. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol 3 ug in 1 g - vectical ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in adults and pediatric patients 2 years and older. the safety and effectiveness of vectical ointment in patients with known or suspected disorders of calcium metabolism have not been evaluated. none risk summary available data from pregnancies that occurred during the clinical development of vectical ointment and published case series of oral and intravenous calcitriol use in pregnant women have not identified a drug associated risk for major birth defects, miscarriages, or adverse maternal or fetal outcomes. in animal reproduction studies, topical administration of calcitriol to pregnant rabbits during the period of organogenesis resulted in an increased incidence of fetal deaths, as well as an increased incidence of minor skeletal abnormalities (see data) . the available data do not allow the calculation of relevant comparisons between the systemic exposures of calcitriol observed in animal studies to the

Amerika Serikat - Inggris - NLM (National Library of Medicine)

bluebay shandong co.,ltd - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - calcitriol -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - calcitriol -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow - sical is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture. sical a is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. sical is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: gelatin; butylated hydroxyanisole; glycerol; iron oxide red; iron oxide yellow; titanium dioxide; medium chain triglycerides; butylated hydroxytoluene; maize starch; sorbitol; mannitol - for the management of established post-menopausal osteoporosis by increasing calcium absorption, elevating circulating levels of calcitriol, and reducing vertebral fracture frequency. for the prevention of corticosteriod-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. for the treatment of hypoclacamia in patients with uraemic osteodystrophy, hypoparathyroidism and vitamin d resistant rickets. indications as at 4 march 2004: rocaltrol is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of a traumatic fracture. rocaltrol is also indicated for the prevention of corticosteriod-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. rocaltrol is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphatemic rickets.